Brian Leyland-Jones

发表

Chapter 22 – Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena

Lance A. Liotta, Virginia Espina, Emanuel F. Petricoin, 2013 .

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

David Wholley, Anne Wallace, Michael Hogarth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

David Cameron, Richard Bell, Mitch Dowsett, 2017, The Lancet.

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2015, American journal of cancer research.

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

Razelle Kurzrock, Brian Leyland-Jones, Melissa Zhao, 2016, JAMA oncology.

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Robert B Livingston, Gordan Srkalovic, Brian Leyland-Jones, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S6-05: High levels of APOBEC3B, a DNA deaminase and an enzymatic source of C-to-T transitions, are a validated marker of poor outcome in estrogen receptor-positive breast cancer

Lodewyk F. A. Wessels, Andreas Schlicker, Scooter Willis, 2013 .

Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay.

Brian Leyland-Jones, G. Sledge, B. Leyland-Jones, 2008, BioTechniques.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Mitch Dowsett, Marion Procter, Brian Leyland-Jones, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutation matters in precision medicine: A future to believe in.

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2017, Cancer treatment reviews.

Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers

Andreas Schlicker, John W. M. Martens, Scooter Willis, 2014, Hormones and Cancer.

Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots.

Shuming Nie, Richard A Moffitt, Brian Leyland-Jones, 2010, ACS nano.

A systems approach to clinical oncology: Focus on breast cancer

Brian Leyland-Jones, B. Leyland-Jones, M. Abramovitz, 2006, Proteome Science.

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells

Pradip De, Brian Leyland-Jones, B. Leyland-Jones, 2018, Scientific Reports.

Breast cancer trial with erythropoietin terminated unexpectedly.

Brian Leyland-Jones, B. Leyland-Jones, 2003, The Lancet. Oncology.

Proteomics: new technologies and clinical applications.

Brian Leyland-Jones, M. Latterich, B. Leyland-Jones, 2008, European journal of cancer.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.